Singular Genomics Systems Temettü

Temettü kriter kontrolleri 0/6

Singular Genomics Systems şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.5%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.5%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Singular Genomics cut to Neutral at UBS on delays for sequencer shipments

Aug 17

Singular Genomics Systems GAAP EPS of -$0.34

Aug 09

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: OMIC şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: OMIC şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Singular Genomics Systems Piyasaya Karşı Temettü Getirisi

OMIC temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (OMIC)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.6%
Sektör Ortalaması (Life Sciences)	0.5%
Analist tahmini (OMIC) (3 yıla kadar)	0%

Önemli Temettü: OMIC şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, OMIC şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: OMIC şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: OMIC herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Singular Genomics Systems Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Concentra Biosciences, LLC submitted non-binding proposal to acquire 85.09% stake in Singular Genomics Systems, Inc. (NasdaqCM:OMIC) for $25.4 million.

Deerfield Mgmt IV, L.P., Deerfield Private Design Fund IV, L.P., funds managed by Deerfield Management Company, L.P. Series C, proposed to acquire remaining 93.34% stake in Singular Genomics Systems, Inc. (NasdaqCM:OMIC) for $25.4 million.

Singular Genomics Systems, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Singular Genomics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Singular Genomics Systems, Inc. to Report Q1, 2024 Results on May 14, 2024

Singular Genomics Systems, Inc., Annual General Meeting, May 29, 2024

Singular Genomics Systems, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Singular Genomics Unveils G4X Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis

Singular Genomics Systems, Inc. Showcases New G4X™ Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4 Sequencing Platform

Singular Genomics Systems to Transfer the Listing of Common Stock from Nasdaq Global Select Market to Nasdaq Capital Market

Singular Genomics Systems to Transfer the Listing of Common Stock from Nasdaq Global Select Market to Nasdaq Capital Market

Singular Genomics Systems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2023

Singular Genomics Systems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2023

Consensus revenue estimates decrease by 44%, EPS upgraded

New minor risk - Share price stability

Fluent BioSciences Inc. Announces A Partnership with Singular Genomics

Singular Genomics Systems, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Consensus revenue estimates decrease by 40%

New minor risk - Shareholder dilution

Price target decreased by 24% to US$0.95

New major risk - Revenue and earnings growth

Singular Genomics Appoints Marcia Eisenberg, Ph.D., to Board of Directors

Singular Genomics Systems, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Singular Genomics Systems Receives Non-Compliance Notice from Nasdaq

Price target decreased by 36% to US$1.25

Founder recently bought US$139k worth of stock

Consensus revenue estimates decrease by 27%, EPS upgraded

Consensus revenue estimates decrease by 10%, EPS upgraded

Singular Genomics Systems, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Singular Genomics Systems, Inc. Launches Max Read Kits for Single Cell Sequencing on the G4 At AGBT

Founder recently bought US$100k worth of stock

Price target decreased to US$2.83

High number of new and inexperienced directors

Singular Genomics Systems, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Consensus forecasts updated

Singular Genomics cut to Neutral at UBS on delays for sequencer shipments

Consensus forecasts updated

Singular Genomics Systems GAAP EPS of -$0.34

Singular Genomics Systems, Inc. Announces Management Appointments

Singular Genomics Systems, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Singular Genomics Systems, Inc.(NasdaqGS:OMIC) dropped from Russell 2000 Growth Index

High number of new and inexperienced directors

Lead Independent Director recently bought US$89k worth of stock

Consensus revenue estimates fall by 18%

Singular Genomics Systems, Inc. Announces the Formation of Scientific Advisory Board

Singular Genomics Systems, Inc. Announces Management Changes

Singular Genomics Systems, Inc., Annual General Meeting, May 26, 2022

Consensus forecasts updated

Singular Genomics Systems, Inc. to Report Q4, 2021 Results on Mar 02, 2022

Singular Genomics Launches the G4 Sequencing Platform

Founder exercised options to buy US$25m worth of stock.

Singular Genomics Systems, Inc. has completed an IPO in the amount of $224.4 million.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin